Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Zeissig MN, et al. Among authors: kondrashova o. Trends Cancer. 2023 Nov;9(11):955-967. doi: 10.1016/j.trecan.2023.07.010. Epub 2023 Aug 15. Trends Cancer. 2023. PMID: 37591766 Free article. Review.
Targeting DNA repair: the genome as a potential biomarker.
Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA. Nesic K, et al. Among authors: kondrashova o. J Pathol. 2018 Apr;244(5):586-597. doi: 10.1002/path.5025. Epub 2018 Feb 10. J Pathol. 2018. PMID: 29282716 Free article. Review.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group. Kondrashova O, et al. Among authors: o malley dm. Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6. Cancer Discov. 2017. PMID: 28588062 Free PMC article. Clinical Trial.
Histone Modifying Enzymes in Gynaecological Cancers.
Ramarao-Milne P, Kondrashova O, Barry S, Hooper JD, Lee JS, Waddell N. Ramarao-Milne P, et al. Among authors: kondrashova o. Cancers (Basel). 2021 Feb 16;13(4):816. doi: 10.3390/cancers13040816. Cancers (Basel). 2021. PMID: 33669182 Free PMC article. Review.
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL. Nesic K, et al. Among authors: kondrashova o. Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28. Cancer Res. 2021. PMID: 34321239
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV; Scottish Genomes Partnership; Cooke SL, Ratnayake G, McNally O, Traficante N; Australian Ovarian Cancer Study12,13; DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Ho GY, et al. Among authors: kondrashova o. Cancer Res. 2022 Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. Cancer Res. 2022. PMID: 36206301 Free PMC article.
The role of aberrant DNA methylation in cancer initiation and clinical impacts.
Geissler F, Nesic K, Kondrashova O, Dobrovic A, Swisher EM, Scott CL, J Wakefield M. Geissler F, et al. Among authors: kondrashova o. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231220511. doi: 10.1177/17588359231220511. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38293277 Free PMC article.
Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
Kondrashova O, Ho GY, Au-Yeung G, Leas L, Boughtwood T, Alsop K, Zapparoli G, Dobrovic A, Ko YA, Hsu AL, Love CJ, Lunke S, Wakefield MJ, McNally O, Quinn M, Ananda S, Neesham D, Hamilton A, Grossi M, Freimund A, Kanjanapan Y, Rischin D, Traficante N, Bowtell D, Scott CL, Christie M, Taylor GR, Mileshkin L, Waring PM; Australian Ovarian Cancer Study Group. Kondrashova O, et al. JCO Precis Oncol. 2019 Dec;3:1-18. doi: 10.1200/PO.19.00019. JCO Precis Oncol. 2019. PMID: 35100705
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.
Wakefield MJ, Nesic K, Kondrashova O, Scott CL. Wakefield MJ, et al. Among authors: kondrashova o. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188307. doi: 10.1016/j.bbcan.2019.08.002. Epub 2019 Aug 2. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31381953 Review. No abstract available.
40 results